The content on this site is intended for healthcare professionals only
Dr Ross Levine presented results from a study on targeting the JAK-STAT pathway in myeloproliferative neoplasms at the EHA 2013.
Myeloproliferative neoplasms (MPN) are clonal blood disorders characterised by excessive production of mature blood cells.
Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.
The identification of somatic mutations in JAK2, MPL and LNK in the majority of MPN patients led to the development of JAK kinase inhibitors.
JAK1/2 inhibitors improve splenomegaly and systemic symptoms, however the mechanism by which this occurs in patients has not been elucidated.
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
More effective treatment options required for patients with MM post lenalidomide exposure
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
